Protocol for monitoring platelet inhibition

Details Protocol for monitoring platelet inhibition Protocol for monitoring platelet inhibition

2007-02-20

2007-02-20

Wallenhorst, Maureen M. (Department: 1743)

Chemistry: analytical and immunological testing

Clotting or clotting factor level tests

C422S073000, C435S013000, C600S368000, C600S369000, C073S064410

Reexamination Certificate

active

10384345

ABSTRACT:
A hemostasis analyzer, such as the Thrombelastograph® (TEG®) hemostasis analyzer is utilized to measure continuously in real time, the hemostasis process from the initial fibrin formation, through platelet-fibrin interaction and lysis to generate blood hemostasis parameters. The measured blood hemostasis parameters permit evaluation of platelet inhibition therapy.

REFERENCES:
patent: 3714815 (1973-02-01), Hartert
patent: 4148216 (1979-04-01), Do et al.
patent: 4193293 (1980-03-01), Cavallari
patent: 4312217 (1982-01-01), Hartert
patent: 4317363 (1982-03-01), Shen
patent: 4328701 (1982-05-01), Mau-Tung et al.
patent: 4695956 (1987-09-01), LeVeen et al.
patent: 5167145 (1992-12-01), Butler et al.
patent: 5223227 (1993-06-01), Zuckerman
patent: 5466582 (1995-11-01), Amiral
patent: 5523238 (1996-06-01), Varon et al.
patent: 5777215 (1998-07-01), Calatzis et al.
patent: 5854423 (1998-12-01), Venegas
patent: 5939276 (1999-08-01), Tomer
patent: 5972712 (1999-10-01), Baugh et al.
patent: 5972717 (1999-10-01), Aster et al.
patent: 6027904 (2000-02-01), Devine et al.
patent: 6060323 (2000-05-01), Jina
patent: 6225126 (2001-05-01), Cohen et al.
patent: 6537819 (2003-03-01), Cohen et al.
patent: 6613573 (2003-09-01), Cohen
patent: 2002/0178126 (2002-11-01), Beck et al.
patent: 2002/0197697 (2002-12-01), Abdelouahed et al.
patent: 2002/0198740 (2002-12-01), Roman et al.
patent: 37 38 901 (1989-05-01), None
patent: 0 018 905 (1980-11-01), None
patent: 0 404 456 (1990-12-01), None
patent: 0 525 273 (1991-02-01), None
patent: 1 226 781 (2002-07-01), None
patent: 1 371 981 (2003-12-01), None
patent: 2 389 137 (1978-11-01), None
patent: 2 004 376 (1979-03-01), None
patent: WO-97/41432 (1997-11-01), None
patent: WO-00/49402 (2000-08-01), None
patent: WO-01/04159 (2001-01-01), None
patent: WO-01/50950 (2001-07-01), None
patent: WO-01/96879 (2001-12-01), None
patent: WO-02/054088 (2002-07-01), None
patent: WO-2004/092742 (2004-10-01), None
Gaetano et al.,Effect of Platelets on Clot Structuration. A Thromebelastographic Study, Thrombosis Research, vol. 3, 1973, pp. 425-435.
Greilich et al.,A Modified Thromboelastographic Method for Monitoring c7E3 Fab in Heparinized Patients, Anesth Analg., vol. 84, 1997, pp. 31-38.
Khurana et al.,Monitoring Platelet Glycoprotein IIb/IIIa-fibrin Interaction With Tissue Factor-Activated Thromboelastography, J Lab Clin Med, 1997, pp. 401-411.
Timmis et al.,Advances in Antiplatelet Therapy in Coronary Artery Disease: Importance of the Platelet GPIIb/IIIa Receptor, Journal of Interventional Cardiology, vol. 10, No. 5, 1997, pp. 327-333.
Ultegra Rapid Platelet Function Assay(RPFA)Bedside Monitoring, Cath-Lab Digest, vol. 7, No. 6, 1999, pp. 1-3.
Ultegra System, Accumetrics Brochure, 2 pages.
Dambisya et al.,Effects of the Platelet-Activating Factor Receptor Antagonist WEB 2086 on Whole Blood Coagulation and Fibrinolysis in a Thromboelastography Assay, Blood Coagulation and Fibrinolysis, vol. 6, 1995, pp. 733-737.
CSA Clot Signature Analyzer—Global Screening Device for Hemostasis, Xylum Corporation, 4 pages.
Orbitometer—The consequent development of the precursory Thrombo-Elastography (Hartert 1947) and of Resonance-Thrombography (Hartert 1977), Heinrich Amelung GmbH, 6 pages.
roTEG Coagulation Analyzer, 1997 Dynabyte Medical, 2 pages.
roTEG Coagulation Analyzer—whole blood coagulation analysis, 4 pages.
elvi 816—Dual Channel, B1 Clot Thromboelastograph, Logos Scientific Inc., 2 pages.
TE-700—New Type Clot-Tracer Model TE-700, Erima, 4 pages (Japanese translation), 2 pages (English translation).
Shore-Lesserson et al., Thromboelastography-Guided Transfusion Algorithm Reduces Transfusions in Complex Cardiac Surgery, Anesthesia and Analgesis (abstract), Feb. 1999, 1 page.
Frenette et al., Effectiveness of Conjugated Estrogen in Orthotopic Liver Transplantation, Southern Medical Journal, vol. 91, Apr. 1998, pp. 365-368.
Nguyen et al., A Web-Based Teaching Program for Laboratory Diagnosis of Coagulation Disorders, Arch. Pathol. Lab. Med., vol. 124, Apr. 2000, pp. 588-593.
International Search Report for Application No. PCT/US03/30710 dated Apr. 21, 2004.
International Search Report for Application No. PCT/US2004/00637 dated Aug. 31, 2004.
Edwards et al., “Successful Use of Argatroban as a Heparin Substitute During Cardiopulmonary Bypass: Heparin-Induced Thrombocytopenia in a High-Risk Cardiac Surgical Patient,” The Annals of Thoracic Surgery, vol. 75, No. 5, May 2003, pp. 1622-1624.
Ammar et al., “In Vitro Effects of the Platelet Glycoprotein IIb/IIIa Receptor Antagonist c7E3 Fab on the Activated Clotting Time,” Circulation, vol. 95, No. 3, Feb. 4, 1997, pp. 614-617.
Koster et al., “Recombinant Hirudin as an Alternative for Anticoagulation During Cardiopulmonary Bypass in Patients,” Journal of Cardiothoracic and Vascular Anesthesia, vol. 14, No. 3, Jun. 2000, pp. 243-248.
Muhl T al., “Therapy and Monitoring of Heparin-Induced Thrombocytopenia Type II in Critically III Patients During Continuous Venovenous Hemodiafiltration: Comparison of aPTT and Ecarin Clotting Time for Monitoring of r-Hirudin Therapy,” Journal of Intensive Care Medicine, vol. 17, No. 1, Jan./Feb. 2002, pp. 34-40.

Affiliated with

Also associated with

Rating

Protocol for monitoring platelet inhibition does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Protocol for monitoring platelet inhibition, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Protocol for monitoring platelet inhibition will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3827498